rs1800625 — AGER AGER -429T>C

Promoter variant at position -429 in the AGER gene that increases RAGE transcription, elevating membrane RAGE and altering soluble sRAGE levels; associated with higher inflammatory signaling through the AGE-RAGE-NF-κB axis and linked to diabetic complications, cancer susceptibility, and sepsis risk

See your personal result for AGER

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

AGER -429T>C — The Promoter Variant That Turns Up RAGE Signaling

The AGER gene encodes RAGE (Receptor for Advanced Glycation End-Products), a pattern recognition receptor11 pattern recognition receptor
A cell-surface protein in the immunoglobulin superfamily that detects molecular damage signals — AGEs, HMGB1, S100 proteins, amyloid-beta — and triggers sustained NF-κB-mediated inflammatory gene expression sitting in the MHC class III region22 MHC class III region
The Major Histocompatibility Complex class III locus on chromosome 6p21.3 — a gene-dense stretch encoding many immunoinflammatory regulators, tightly linked to immune response haplotypes including the 8.1 ancestral haplotype associated with autoimmune susceptibility of chromosome 6. RAGE is expressed on endothelial cells, immune cells, neurons, alveolar epithelium, adipocytes, and cardiomyocytes. When its ligands bind — particularly advanced glycation end-products (AGEs) formed from proteins and lipids modified by sugars — RAGE activates NF-κB and MAPK cascades, driving a self-amplifying inflammatory loop.

The rs1800625 variant sits 429 base pairs upstream of the AGER transcription start site in the gene's promoter region. The G allele (described in older literature as the -429C allele using coding-strand notation, because AGER is on the minus strand) alters transcription factor binding at the promoter, increasing RAGE expression. In vitro, the risk allele elevates RAGE transcription approximately twofold and is also associated with higher circulating levels of soluble RAGE (sRAGE) — a decoy receptor33 decoy receptor
The soluble, extracellular domain of RAGE that circulates in blood, binding AGEs and other RAGE ligands before they reach membrane-bound RAGE on cells, thereby dampening RAGE-mediated inflammatory signaling isoform. This creates a complex picture: greater membrane RAGE plus greater sRAGE — more signaling potential, partially counterbalanced by more circulating decoy.

The Mechanism

The AGER promoter contains functional binding sites for NF-κB and SP1 transcription factors. The -429T>C transition (plus-strand A>G) lies within a regulatory element that modulates baseline and stimulus-driven RAGE transcription. The G/risk allele enhances promoter activity, increasing both membrane RAGE and the splice variant that generates soluble sRAGE, as demonstrated in luciferase reporter and cell culture assays. In conditions of elevated ligand load — chronic hyperglycemia, aging-related AGE accumulation, high-AGE diets, or acute inflammatory stress — the greater membrane RAGE density in G allele carriers means more AGE-RAGE-NF-κB signaling reaches cells.

The rs1800625 variant is in strong linkage disequilibrium44 strong linkage disequilibrium
Two variants in LD are inherited together more often than expected by chance — making it difficult to determine which variant is causal versus merely tagging the causal one with the -374T>A (rs1800624) promoter variant and is part of the HLA 8.1 ancestral haplotype55 HLA 8.1 ancestral haplotype
A conserved MHC haplotype (carrying HLA-A1, HLA-B8, HLA-DR3, HLA-DQ2) found in ~8-10% of Northern Europeans and strongly associated with multiple autoimmune conditions including type 1 diabetes, celiac disease, and systemic lupus erythematosus, as documented by Laki et al. (2007)66 Laki et al. (2007)
Laki J et al. The HLA 8.1 ancestral haplotype is strongly linked to the C allele of -429T>C RAGE gene polymorphism. Oral Dis, 2006. This haplotype context complicates causal interpretation — some disease associations attributed to the -429C/G variant may partly reflect co-inherited immune-related variants in the broader 8.1 haplotype.

The Evidence

Glycemic control. Laki et al. (2007) studied 82 unrelated type 1 diabetic patients and found that the -429C/G allele was independently associated with elevated HbA1c77 independently associated with elevated HbA1c levels regardless of haplotype status, suggesting a direct functional effect on glycemic trajectory beyond the 8.1 haplotype association.

Diabetic complications. A Pakistani study by Qayyum et al. (2021)88 Qayyum et al. (2021)
Qayyum A et al. Association analysis of -429T/C RAGE gene polymorphism with type 2 diabetic retinopathy and serum soluble RAGE levels. J Pak Med Assoc, 2021 found that the C/G allele was significantly more common in type 2 diabetic patients with retinopathy than in controls (OR>1.5), and was also associated with higher circulating sRAGE — consistent with the in vitro upregulation data.

Cancer susceptibility. A meta-analysis by Xu et al. (2019)99 Xu et al. (2019)
Xu Y et al. Association of RAGE rs1800625 polymorphism and cancer risk: A meta-analysis of 18 case-control studies. Med Sci Monit, 2019 pooled 6,246 cancer cases and 6,819 controls from 18 studies. The CC/GG homozygous genotype was associated with increased cancer risk in the recessive model (OR=1.40, 95%CI 1.03–1.89, P=0.031), with the association driven predominantly by Asian populations; Caucasian-specific analysis did not reach significance. Cancer types studied included gastric, colorectal, lung, liver, and urothelial cancers.

Sepsis and trauma. A prospective Chinese study by Zeng et al. (2015)1010 Zeng et al. (2015)
Zeng L et al. Rs1800625 in the receptor for advanced glycation end products gene predisposes to sepsis and multiple organ dysfunction syndrome in patients with major trauma. Crit Care, 2015 (n=451 trauma patients) found that the C/G allele was associated with lower sepsis morbidity and reduced multiple organ dysfunction syndrome (MODS) scores. Carriers of the CC/GG genotype had significantly fewer sepsis-related complications than TT/AA homozygotes — an apparently protective effect in acute inflammatory stress that may reflect the variant's influence on the sRAGE decoy pool under extreme ligand load.

Metabolic liver disease. In 340 obese patients with metabolic syndrome, a RAGE gene haplotype including rs1800625 was associated with 2-fold increased risk of non-alcoholic steatohepatitis (NASH), as reported by Mehta et al. (2018)1111 Mehta et al. (2018)
Mehta R et al. Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for NASH. PLOS One, 2018.

Practical Actions

The primary actionable target is the AGE load that activates RAGE. Dietary AGEs — formed by high-heat dry cooking of proteins and fats — are absorbed and bind RAGE directly. Switching to moist-heat cooking (boiling, steaming, slow cooking, poaching) reduces dietary AGE intake by 50–70%. Controlling blood glucose is equally important: chronic hyperglycemia accelerates endogenous AGE formation, compounding the promoter-driven upregulation of membrane RAGE. Monitoring HbA1c is particularly relevant given the variant's association with glycemic excursions and diabetic complication risk.

Interactions

The rs1800625 promoter variant interacts with the rs2070600 coding variant (Gly82Ser) in the same gene. Haplotype analyses show that combined promoter + coding variants may have stronger effects on total RAGE pathway activity than either SNP alone. The -429 and -374 promoter variants (rs1800625 and rs1800624) are themselves in strong LD and often co-inherited as part of the HLA 8.1 ancestral haplotype, making it important to interpret rs1800625 findings in the context of the broader AGER haplotype background. Users carrying both rs1800625 G and rs2070600 T alleles may have the most pronounced upregulation of total RAGE signaling — a compound interaction worth evaluating.

Genotype Interpretations

What each possible genotype means for this variant.

AA Standard RAGE Promoter Normal

Common promoter genotype with typical RAGE transcriptional activity

With the AA genotype, the AGER promoter at position -429 maintains its baseline transcription factor binding profile without the altered binding that the G allele introduces. Your circulating and membrane RAGE levels at this locus reflect typical population expression, meaning the AGE-RAGE- NF-κB inflammatory loop operates at its standard baseline rate.

This does not mean RAGE signaling is irrelevant to you — all humans accumulate AGEs with age, diabetes, and high-heat diet exposure, and membrane RAGE activation is a universal inflammatory driver. It means that at this specific regulatory site, you do not carry the upregulation variant that shifts RAGE expression higher.

AG RAGE Promoter Carrier Intermediate

One copy of the promoter variant — moderately elevated RAGE transcription

As a heterozygous carrier, one copy of your AGER promoter carries the enhanced transcription allele. The promoter-enhancing effect is partially dose-dependent — you have more RAGE expression than AA homozygotes but less than GG carriers. The functional significance depends on your AGE load: under conditions of chronic hyperglycemia or high dietary AGE exposure, even moderate upregulation of membrane RAGE can amplify NF-κB-mediated inflammatory signaling.

The rs1800625 G allele in heterozygous form is also associated with the HLA 8.1 ancestral haplotype in many European populations, which itself carries elevated autoimmune susceptibility. If you have a personal or family history of autoimmune conditions, this haplotype context may be relevant.

The 2019 cancer meta-analysis found that pooled analyses favored a recessive model (GG vs TC+TT), so heterozygote cancer risk findings are less consistent. The diabetic HbA1c and retinopathy associations appear dose-related, suggesting AG carriers may have intermediate glycemic risk.

GG RAGE Promoter Risk Genotype High Risk

Two copies of the upregulatory promoter variant — elevated RAGE transcription and inflammatory signaling capacity

With two G alleles, both copies of your AGER promoter drive enhanced RAGE transcription. The functional consequence is an upregulated AGE-RAGE-NF-κB inflammatory circuit with potentially greater responsiveness to RAGE ligands (AGEs, HMGB1, S100 proteins). In vitro data show approximately twofold higher RAGE promoter activity for the risk genotype compared to TT/AA homozygotes.

The cancer risk finding from the Xu et al. (2019) meta-analysis used a recessive model where GG homozygotes showed OR=1.40 for cancer susceptibility across 18 studies (6,246 cases) in Asian populations. The elevated cancer risk is consistent with chronic NF-κB activation — a known driver of oncogenic transformation in inflammatory microenvironments.

The HbA1c association is notable because it suggests that beyond baseline diabetes risk, the GG genotype may impair glycemic control in people who already have diabetes — a potentially self-amplifying dynamic where hyperglycemia forms more AGEs, which bind more RAGE (upregulated by this variant), which drives more NF-κB and inflammatory damage to pancreatic beta cells and insulin-sensitive tissues.

In the sepsis and major trauma context, the C/G allele paradoxically appeared protective (lower MODS scores) in the Zeng et al. (2015) trauma study — possibly because under extreme acute inflammation, elevated sRAGE from the upregulated promoter provides more decoy buffering of circulating damage signals. This context-dependent directionality (risk in chronic metabolic disease, possibly protective in acute injury) is characteristic of RAGE pathway variants.

The haplotype context matters: in Northern Europeans, GG carriers at this locus often co-inherit the HLA 8.1 ancestral haplotype, which independently elevates autoimmune risk. If you have European ancestry, checking your HLA haplotype may provide additional context.